Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 35 articles:
HTML format



Single Articles


    June 2022
  1. SMITH MR
    Darolutamide in Metastatic Prostate Cancer. Reply.
    N Engl J Med. 2022;386:2345.
    PubMed    


  2. BOWLING GC, Dimitrakoff JD
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    


  3. TURCO F, Tucci M, Buttigliero C
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    


    February 2022
  4. SMITH MR, Hussain M, Saad F, Fizazi K, et al
    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    N Engl J Med. 2022 Feb 17. doi: 10.1056/NEJMoa2119115.
    PubMed     Abstract available


    December 2021
  5. SARTOR O, Morris MJ, Kraus BJ
    Lutetium-177-PSMA-617 for Prostate Cancer. Reply.
    N Engl J Med. 2021;385:2495-2496.
    PubMed    


  6. DALLA VOLTA A, Grisanti S, Berruti A
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2495.
    PubMed    


  7. KASHIHARA T, Kashihara K
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494-2495.
    PubMed    


  8. HINDIE E
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494.
    PubMed    


    November 2021
  9. EKLUND M, Discacciati A, Nordstrom T
    MRI-Targeted Biopsy in Prostate Cancer Screening. Reply.
    N Engl J Med. 2021;385:2110-2111.
    PubMed    


  10. YOSHIDA S, Fujii Y
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2110.
    PubMed    


  11. AL HUSSEIN AL AWAMLH B, Spratt DE, Shoag JE
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2109-2110.
    PubMed    


    July 2021
  12. EKLUND M, Jaderling F, Discacciati A, Bergman M, et al
    MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852.
    PubMed     Abstract available


    June 2021
  13. SARTOR O, de Bono J, Chi KN, Fizazi K, et al
    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMoa2107322.
    PubMed     Abstract available


    March 2021
  14. HUSSAIN M, Desai C, de Bono J
    Olaparib in Metastatic Castration-Resistant Prostate Cancer. Reply.
    N Engl J Med. 2021;384:1175-1176.
    PubMed    


  15. SMITH TJ
    Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021;384:1175.
    PubMed    


  16. BISWAS B, Ganguly S, Ghosh J
    Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021;384:1174-1175.
    PubMed    


  17. MCCAW ZR, Liu MA, Wei LJ
    Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021;384:1174.
    PubMed    


    December 2020
  18. ARAP W, Pasqualini R, Costello JF
    Prostate Cancer Progression and the Epigenome.
    N Engl J Med. 2020;383:2287-2290.
    PubMed    


    September 2020
  19. SHOAG JE, Nyame YA, Hu JC
    Reconsidering the Trade-offs of Prostate Cancer Screening. Reply.
    N Engl J Med. 2020;383:1290.
    PubMed    


  20. WITTMANN D, Skolarus T, Glode LM
    Reconsidering the Trade-offs of Prostate Cancer Screening.
    N Engl J Med. 2020;383:1289-1290.
    PubMed    


  21. HUSSAIN M, Mateo J, Fizazi K, Saad F, et al
    Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020 Sep 20. doi: 10.1056/NEJMoa2022485.
    PubMed     Abstract available


  22. MAHAL BA, Alshalalfa M, Kensler KH, Chowdhury-Paulino I, et al
    Racial Differences in Genomic Profiling of Prostate Cancer.
    N Engl J Med. 2020;383:1083-1085.
    PubMed    


  23. FIZAZI K, Shore N, Tammela TL, Ulys A, et al
    Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
    N Engl J Med. 2020;383:1040-1049.
    PubMed     Abstract available


    August 2020
  24. DE BONO J, Kang J, Hussain M
    Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply.
    N Engl J Med. 2020;383:891.
    PubMed    


  25. HEIDEGGER I, Pircher A
    Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020;383:890-891.
    PubMed    


  26. MUTETWA T, Foulkes WD, Polak P
    Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020;383:890.
    PubMed    


    June 2020
  27. SHOAG JE, Nyame YA, Gulati R, Etzioni R, et al
    Reconsidering the Trade-offs of Prostate Cancer Screening.
    N Engl J Med. 2020;382:2465-2468.
    PubMed    


  28. AHDOOT M, Turkbey B, Pinto P
    Biopsy for Prostate Cancer Diagnosis. Reply.
    N Engl J Med. 2020;382:2271.
    PubMed    


  29. STANZIONE A, Imbriaco M, Cuocolo R
    Biopsy for Prostate Cancer Diagnosis.
    N Engl J Med. 2020;382:2270-2271.
    PubMed    


  30. SCHOLZ M, Lam R, Turner J
    Biopsy for Prostate Cancer Diagnosis.
    N Engl J Med. 2020;382:2270.
    PubMed    


    May 2020
  31. HIGANO CS
    Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMe2016433.
    PubMed    


  32. STERNBERG CN, Fizazi K, Saad F, Shore ND, et al
    Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMoa2003892.
    PubMed     Abstract available


  33. SHORE ND, Saad F, Cookson MS, George DJ, et al
    Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    N Engl J Med. 2020 May 29. doi: 10.1056/NEJMoa2004325.
    PubMed     Abstract available


    April 2020
  34. DE BONO J, Mateo J, Fizazi K, Saad F, et al
    Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2020 Apr 28. doi: 10.1056/NEJMoa1911440.
    PubMed     Abstract available


  35. WELCH HG, Albertsen PC
    Reconsidering Prostate Cancer Mortality - The Future of PSA Screening.
    N Engl J Med. 2020;382:1557-1563.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: